The University of Pittsburgh Cancer Institute (UPCI) offers a fellowship in stereotactic radiosurgery and stereotactic body radiotherapy (SRS/SBRT). This 12-month program (optional 24 months) integrates patient-centered clinical oncology with the opportunity to engage in cutting-edge research. The preliminary clinical training will be focused on the application of SRS/SBRT to treat malignant and benign tumors of the brain, base of skull, head and neck, lung, spine, pancreas, and pelvis with an evidence-based approach. The clinical experience includes benign tumors as well as functional disorders (trigeminal neuralgia, essential/Parkinsonian tremors).
Along with clinical training, the fellow will be able to obtain mastery of multiple SRS/SBRT platforms including Cyberknife®, Gamma Knife®, Trilogy™, and Synergy®. The ability to acquire training on the major radiosurgical platforms is a unique attribute of the program at the University of Pittsburgh.
The research component of the training focuses on:
The Department of Radiation Oncology at UPCI has a robust research infrastructure and has contributed much to the body of literature, and so the fellow is expected to continue and augment this.
UPMC Shadyside was recognized at the February 2011 Cyberknife® International Meeting. UPMC received the following honors: #1 in United States for overall treatment volume; #4 in the world for overall treatment volume' #1 in the World for CNS Treatment. This is the 5th year that UPMC Shadyside has been in the top 5 business Cyberknife® sites worldwide.
2012-2013 Fellow
Michelle Olsheski, MD
SUNY Downstate Medical Center
Residency Temple University School of Medicine
2013-2015 Fellow
Kimmen Quan, MD
Juravinski Cancer Centre, Hamilton Health Sciences, McMaster University
Residency St. George's University School of Medicine